181 related articles for article (PubMed ID: 38043787)
1. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
[TBL] [Abstract][Full Text] [Related]
2. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
Ding GY; Ma JQ; Yun JP; Chen X; Ling Y; Zhang S; Shi JY; Chang YQ; Ji Y; Wang XY; Tan WM; Yuan KF; Yan B; Zhang XM; Liang F; Zhou J; Fan J; Zeng Y; Cai MY; Gao Q
J Hepatol; 2022 Mar; 76(3):608-618. PubMed ID: 34793865
[TBL] [Abstract][Full Text] [Related]
3. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
4. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
[TBL] [Abstract][Full Text] [Related]
5. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
6. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.
Lin J; Dai Y; Sang C; Song G; Xiang B; Zhang M; Dong L; Xia X; Ma J; Shen X; Ji S; Zhang S; Wang M; Fang H; Zhang X; Wang X; Zhang B; Zhou J; Fan J; Zhou H; Gao D; Gao Q
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863823
[TBL] [Abstract][Full Text] [Related]
7. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
8. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma.
Song G; Shi Y; Meng L; Ma J; Huang S; Zhang J; Wu Y; Li J; Lin Y; Yang S; Rao D; Cheng Y; Lin J; Ji S; Liu Y; Jiang S; Wang X; Zhang S; Ke A; Wang X; Cao Y; Ji Y; Zhou J; Fan J; Zhang X; Xi R; Gao Q
Nat Commun; 2022 Mar; 13(1):1642. PubMed ID: 35347134
[TBL] [Abstract][Full Text] [Related]
9. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
[TBL] [Abstract][Full Text] [Related]
10. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
11. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract][Full Text] [Related]
12. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
13. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
14. Spatial multimodal analysis revealed tertiary lymphoid structures as a risk stratification indicator in combined hepatocellular-cholangiocarcinoma.
Gan X; Dong W; You W; Ding D; Yang Y; Sun D; Li W; Ding W; Liang Y; Yang F; Zhou W; Dong H; Yuan S
Cancer Lett; 2024 Jan; 581():216513. PubMed ID: 38036041
[TBL] [Abstract][Full Text] [Related]
15. Tertiary lymphoid structures correlate with enhancement of antitumor immunity in esophageal squamous cell carcinoma.
Nakamura S; Ohuchida K; Hayashi M; Katayama N; Tsutsumi C; Yamada Y; Hisano K; Okuda S; Ohtsubo Y; Iwamoto C; Torata N; Mizuuchi Y; Shindo K; Nakata K; Moriyama T; Morisaki T; Oda Y; Nakamura M
Br J Cancer; 2023 Oct; 129(8):1314-1326. PubMed ID: 37604932
[TBL] [Abstract][Full Text] [Related]
16. Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.
Lin Y; Peng L; Dong L; Liu D; Ma J; Lin J; Chen X; Lin P; Song G; Zhang M; Liu Y; Rao J; Wei C; Lu Y; Zhang S; Ding G; Peng Z; Lu H; Wang X; Zhou J; Fan J; Wu K; Gao Q
Cancer Discov; 2022 Oct; 12(10):2350-2371. PubMed ID: 35853232
[TBL] [Abstract][Full Text] [Related]
17. SUOX and GLUT1 are biomarkers for the prognosis in large duct type intrahepatic cholangiocarcinoma.
Kinjo Y; Naito Y; Akiba J; Sadashima E; Nakayama M; Tanigawa M; Hisaka T; Okabe Y; Yano H
Hum Pathol; 2022 Oct; 128():11-19. PubMed ID: 35764144
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.
Kinzler MN; Schulze F; Jeroch J; Schmitt C; Ebner S; Gretser S; Bein J; Finkelmeier F; Trojan J; Zeuzem S; Schnitzbauer AA; Demes MC; Reis H; Wild PJ; Walter D
Histopathology; 2024 May; 84(6):1061-1067. PubMed ID: 38409827
[TBL] [Abstract][Full Text] [Related]
20. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
